Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5899]

ASCO 2026: Combining targeted immunotherapies with standard R-CHOP delays progression of aggressive B-cell lymphomas

ASCO 2026: Combining targeted immunotherapies with standard R-CHOP delays progression of aggressive B-cell...

ASCO 2026: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer

ASCO 2026: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer

Multidrug treatment using nanofibers shows promise for glioblastoma

Multidrug treatment using nanofibers shows promise for glioblastoma

Naturally occurring molecule may help outsmart melanoma

Naturally occurring molecule may help outsmart melanoma

Breast cancer: New approach to improve the effectiveness of immunotherapies

Breast cancer: New approach to improve the effectiveness of immunotherapies

KRAS degradation induces rapid lung cancer regression in preclinical mouse models

KRAS degradation induces rapid lung cancer regression in preclinical mouse models

CHMP issues positive opinion for encorafenib in combination with cetuximab and FOLFOX for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer

CHMP issues positive opinion for encorafenib in combination with cetuximab and FOLFOX for the first-line treatment...

TGIF2-mediated HMGB3 overexpression drives oesophageal squamous cell carcinoma (ESCC)

TGIF2-mediated HMGB3 overexpression drives oesophageal squamous cell carcinoma (ESCC)

Vitamin D analog shuts down pancreatic cancer’s shield in clinical trial

Vitamin D analog shuts down pancreatic cancer’s shield in clinical trial

ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST

ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST

More from ecancer